Write reviews, get FREE cbd products
Business Featured Health Research

$2 Million Going To Cannabis Cancer Research Led By Professor Mechoulam

mechoulam cancer
Written by Alexandra Hicks
Premium CBD Softgels - Buy one get one free!

A cannabis-based treatment for cancer may finally be on the horizon, thanks to the research of none-other-than Professor Raphael Mechoulam.

Mechoulam is leading a research team to work on developing cannabis-based treatments for three aggressive forms of cancer: melanoma (skin cancer), neuroblastoma (cancer originating in the surrounding and mostly neural system in children), and glaublastoma (brain cancer).

The ongoing research will be funded by Tel Aviv-listed cannabis producer Cannbit, who will invest an initial $400,000 towards the cannabis research, and an additional $2,000,000 for a commercial medicine license. Former Israeli Air Force commander Eitan Ben Eliyahu is the chairman of Cannbit and Mechoulam is currently operating as head of Cannbit’s scientific advisory committee.

In exchange, Cannbit will receive rights to sell this medicine for the duration of its patent – 25 years. The rest of the partners will get 13% from all future revenue from the research and the sale of the medicine, as well as any future intellectual property stemming from this research.

The Hebrew University’s technology transfer company, Yissum, owns the IP for the results of the preliminary study. Ownership will eventually be transferred to Cannbit for the duration of the patent. Hadassah University Hospital-Ein Kerem and Sheba Medical Center will also collaborate on the study.

Mechoulam, a professor of medicinal chemistry at Hebrew University, is known as the father of medical cannabis since discovering endocannabinoids and phytocannabinoids back in 1964. He and his research group were the first to isolate the major plant cannabinoids tetrahydrocannabinol, cannabidiol, cannabigerol and many others.

Check back with us for more updates on these groundbreaking cannabis studies.

To learn more about Raphael Mechoulam and medical cannabis, click on the image below to listen to an exclusive interview conducted by our friends at CannaCAST IL.

mechoulam interview

Learn more about CBD, THC or cannabis studies

About the author

Alexandra Hicks

Alexandra is the managing editor at CBD Testers. She has always been interested in alternative and natural remedies, and the versatility of cannabis as a healing plant is something that greatly appeals to her. It's for this reason that she decided to work as a cannabis industry journalist and editor, to help spread accurate information about the benefits of this plant.

1 Comment

  • Dear Alexandra

    Cannmedeventsare is excited to welcome CannMed co-founder and Israeli chemist, Professor Raphael Mechoulam, as he has confirmed that he will present in-person as keynote on Monday, September 23rd. In recognition for his lifelong commitment to advancing medicinal cannabis, we have planned a few special opportunities for the event attendees to show there appreciation to him and his wife.

    – Attendees have the option joining us at a VIP reception and dinner on Monday, September 23rd. We have developed a special program with the CEO and co-founder of EPM, Reshef Swisa. Following his presentation and launch of EPM’s Cannabinoid Acid Platform, Mr. Swisa and I, will award Professor Mechoulam with a lifetime achievement award.

    – Eight (40 square foot) windows will be decorated with window clings designed to tell the story of Professor Mechoulam life and work in the cannabis sector. The beautifully designed panels will include never seen before pictures reflecting the various aspects of his life and career.

    – Guests of the conference also have the opportunity of sponsoring pages to express their thanks to Professor Mechoulam and his wife in a commemorative book. Pages can be purchased by individuals, companies, and groups.

    Please feel free to let me know if you have any questions.

    Regards

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: